Equity Overview
Price & Market Data
Price: $37.18
Daily Change: +$0.55 / 1.48%
Daily Range: $36.20 - $37.24
Market Cap: $6,925,444,096
Daily Volume: 833,112
Performance Metrics
1 Week: -0.21%
1 Month: -1.82%
3 Months: -8.69%
6 Months: -13.43%
1 Year: -18.54%
YTD: -15.00%
Company Details
Employees: 534
Sector: Health technology
Industry: Pharmaceuticals: other
Country:
Details
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291), and zoldonrasib G12D (RMC-9805), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C). The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; RMC-5552, a selective inhibitor of mTORC1 signaling in tumors, which is in phase 1 clinical trial; and RMC-5845 that targets SOS1. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.